Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427251 | 0.82 | MAPK14 (0.39) | MAPK14PDGFRBCYP3A4 | |
| SCHEMBL24427335 | 0.74 | CYP2A6 (0.38) | MAPK14EPHX2LMNACHRNA7HTR3A | |
| SCHEMBL15108909 | 0.70 | CHRNA7 (0.51) | MAPK14EPHX2CHRNA7HTR3A | |
| SCHEMBL24726560 | 0.68 | CYP11B1 (0.42) | EPHX2CYP3A4 | |
| SCHEMBL24427626 | 0.67 | MAPK14 (0.39) | MAPK14PDGFRB | |
| SCHEMBL24427514 | 0.66 | PDPK1 (0.52) | — | |
| SCHEMBL26633206 | 0.66 | EPHX2 (0.39) | EPHX2CHRNA7HTR3A | |
| SCHEMBL17832298 | 0.64 | KDM4E (0.42) | MAPK14MAPK11CYP3A4KMT2A | |
| SCHEMBL22845366 | 0.64 | EPHX2 (0.50) | EPHX2CHRNA7HTR3A | |
| SCHEMBL24427524 | 0.63 | SCN9A (0.46) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | MAPK14 282/4885EPHX2 2990/4885PDGFRB 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.